SCHEMBL1616294

SCHEMBL1616294

[CH2]/C=C/c1ccoc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616295 1.00
SCHEMBL9454497 0.76
SCHEMBL10192448 0.75
SCHEMBL9454495 0.75
SCHEMBL9454491 0.75
SCHEMBL7755759 0.75
SCHEMBL467876 0.74
SCHEMBL9584211 0.73 MAPT (0.56)
SCHEMBL9584227 0.73 MAPT (0.56)
SCHEMBL5321711 0.73 HCAR2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670406-B1 COMBINATION THERAPY WITH INTERFERON BETA AND ANDROGRAPHOLIDES FOR MULTIPLE SCLEROSIS INNOBIOSCIENCE LLC (US) 2015-09-02 EP claimed
US-9060994-B2 Combination therapy with interferon and andrographolides for Multiple Sclerosis Inno Biosciences, S.p.A. (CL) 2015-06-23 US claimed
US-20140301981-A1 Combination Therapy with Interferon and Andrographolides for Multiple Sclerosis INNOBIOSCIENCE LLC (US) 2014-10-09 US claimed
EP-2670406-A1 COMBINATION THERAPY WITH INTERFERON AND ANDROGRAPHOLIDES FOR MULTIPLE SCLEROSIS Herbal Powers Corporation (US) 2013-12-11 EP claimed
WO-2013096423-A1 COMBINATION THERAPY WITH INTERFERON AND ANDROGRAPHOLIDES FOR MULTIPLE SCLEROSIS Herbal Powers Corporation (US) 2013-06-27 WO claimed
US-20220409573-A1 Hippocampus Regeneration And Memory Recovery INNOBIOSCIENCE, LLC (US) 2022-12-29 US disclosed
US-10722492-B2 Andrographolide treats progressive forms of multiple sclerosis Inno Bioscience, LLC (US) 2020-07-28 US disclosed
US-20190083458-A1 Andrographolide Treats Progressive Forms of Multiple Sclerosis INNOBIOSCIENCES, LLC (US) 2019-03-21 US disclosed
US-9060994-B2 Combination therapy with interferon and andrographolides for Multiple Sclerosis Inno Biosciences, S.p.A. (CL) 2015-06-23 US disclosed
US-20140301981-A1 Combination Therapy with Interferon and Andrographolides for Multiple Sclerosis INNOBIOSCIENCE LLC (US) 2014-10-09 US disclosed
EP-1794122-B1 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMA INC (US) 2011-05-04 EP disclosed
US-7923466-B2 treating in a lengthening of circadian rhythm period with 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide; for treating central nervous system diseases and mood disorders, bipolar disorder and sleep disorders, with an enzyme inhibitor AVENTIS PHARMACEUTICALS INC. (US) 2011-04-12 US disclosed
US-7629376-B2 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I AVENTIS PHARMACEUTICALS INC. (US) 2009-12-08 US disclosed
US-20090082340-A1 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMACEUTICALS INC. (US) 2009-03-26 US disclosed
US-20080027124-A1 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMACEUTICALS INC. (US) 2008-01-31 US disclosed
US-20040023882-A1 PTH derivatives resistant to skin proteases THERATECHNOLOGIES INC. (CA) 2004-02-05 US disclosed
WO-2003097690-A2 PTH DERIVATIVES RESISTANT TO SKIN PROTEASES THERATECHNOLOGIES INC. (CA) 2003-11-27 WO disclosed